. home.aspx

NEWS

home.aspx
   


Boehringer enriches cancer immunology portfolio with AMAL Therapeutics acquisition

July 17, 2019 / Anna Smith
SHARESHARESHARE

Boehringer Ingelheim has announced its acquisition of all shares of AMAL Therapeutics, a private Swiss biotechnology company focused on cancer immunotherapy. AMAL’s lead vaccine ATP128 is currently developed for stage IV colorectal cancer and is slated to begin first-in-human trials later this month, and Boehringer Ingelheim plans to develop new therapies by combining assets from its cancer immunology portfolio with AMAL’s proprietary KISIMA immunisation platform. “Acquiring AMAL is part of Boehringer Ingelheim’s long-term strategy to enhance our existing position as an innovator of novel cancer therapies, including immuno-oncology treatments, which leverage cutting-edge scientific discoveries and their applications,” said Michel Pairet, member of Boehringer Ingelheim’s board of managing directors. He continued, “We want to pioneer new paradigms of biology-based care for cancer patients, and the technologies and expertise developed at AMAL are ...